Recent advancements in gastrointestinal health highlight the potential of microbiota manipulation in treating conditions such as Irritable Bowel Syndrome (IBS) and Inflammatory Bowel Disease (IBD). Research indicates that dietary treatments may be more effective than traditional medicines for IBS, as demonstrated in a study published in The Lancet. Additionally, probiotics, prebiotics, synbiotics, and fecal microbiota transplantation (FMT) are being explored for their ability to induce clinical remission in IBD by reducing inflammation. Specifically, the probiotic Bifidobacterium longum CECT 7347, both in its regular and heat-treated forms, has shown efficacy in improving symptoms of diarrhea-predominant IBS. Moreover, a controllable extracellular vesicles-produced system targeting microbiota for human therapeutics has been developed.
A multi-strain synbiotic ⬆️short-chain fatty acid levels. #MedTwitter #GITwitter #microbiome #probiotics https://t.co/888iDD0T45
#Probiotic Bifidobacterium longum CECT 7347 and heat-treated Bifidobacterium longum CECT 7347 improved symptoms of diarrhea-predominant irritable bowel syndrome. #MedTwitter #GITwitter #IBS #microbiome #probiotics https://t.co/NdWvFHby30
Dietary treatment found to be more effective than medicines in #irritableBowelSyndrome @TheLancet https://t.co/A6HFlI7GGf
Finally, a controllable extracellular vesicles-produced system targeting #microbiota for human therapeutics @NatureComms https://t.co/3d2DWdikK3
Although current treatment options for #IBD induce clinical remission by reducing inflammation, the authors of a recent paper indicate that targeted #microbiota manipulation using probiotics, prebiotics, synbiotics, and FMT holds potential https://t.co/ZPIldIYub5 @physicianswkly